June 15, 2020
AbbVie said on June 12 that it has filed its rheumatoid arthritis (RA) treatment Rinvoq (upadacitinib), an oral JAK inhibitor, in Japan, seeking an additional indication for the treatment of psoriatic arthritis in patients who have an inadequate response to...read more